image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - IE
$ 26.81
-0.446 %
$ 3.66 B
Market Cap
-25.06
P/E
1. INTRINSIC VALUE

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names.[ Read More ]

The intrinsic value of one PRGO stock under the base case scenario is HIDDEN Compared to the current market price of 26.8 USD, Perrigo Company plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PRGO

image
FINANCIALS
4.66 B REVENUE
4.58%
152 M OPERATING INCOME
-12.09%
-12.7 M NET INCOME
90.97%
406 M OPERATING CASH FLOW
31.96%
-77.5 M INVESTING CASH FLOW
96.04%
-187 M FINANCING CASH FLOW
-44.40%
1.09 B REVENUE
2.05%
80.4 M OPERATING INCOME
24.07%
-25.7 M NET INCOME
75.69%
42.2 M OPERATING CASH FLOW
344.21%
213 M INVESTING CASH FLOW
390.18%
653 M FINANCING CASH FLOW
1411.85%
Balance Sheet Decomposition Perrigo Company plc
image
Current Assets 2.83 B
Cash & Short-Term Investments 751 M
Receivables 740 M
Other Current Assets 1.34 B
Non-Current Assets 7.98 B
Long-Term Investments 92.3 M
PP&E 1.1 B
Other Non-Current Assets 6.78 B
Current Liabilities 1.59 B
Accounts Payable 478 M
Short-Term Debt 439 M
Other Current Liabilities 670 M
Non-Current Liabilities 4.45 B
Long-Term Debt 3.81 B
Other Non-Current Liabilities 649 M
EFFICIENCY
Earnings Waterfall Perrigo Company plc
image
Revenue 4.66 B
Cost Of Revenue 2.98 B
Gross Profit 1.68 B
Operating Expenses 1.53 B
Operating Income 152 M
Other Expenses 165 M
Net Income -12.7 M
RATIOS
36.09% GROSS MARGIN
36.09%
3.26% OPERATING MARGIN
3.26%
-0.27% NET MARGIN
-0.27%
-0.27% ROE
-0.27%
-0.12% ROA
-0.12%
0.91% ROIC
0.91%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Perrigo Company plc
image
Net Income -12.7 M
Depreciation & Amortization 360 M
Capital Expenditures -102 M
Stock-Based Compensation 68.8 M
Change in Working Capital -58.5 M
Others 200 M
Free Cash Flow 304 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Perrigo Company plc
image
Wall Street analysts predict an average 1-year price target for PRGO of $35 , with forecasts ranging from a low of $30 to a high of $39 .
PRGO Lowest Price Target Wall Street Target
30 USD 11.90%
PRGO Average Price Target Wall Street Target
35 USD 30.55%
PRGO Highest Price Target Wall Street Target
39 USD 45.47%
4. DIVIDEND ANALYSIS
1.07% DIVIDEND YIELD
0.276 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Perrigo Company plc
image
Sold
0-3 MONTHS
1.6 M USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
27.9 K USD 1
3-6 MONTHS
526 K USD 3
6-9 MONTHS
757 K USD 4
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 13, 2024
Sell 244 K USD
Doyle Katherine C.
Director
- 8954
27.3 USD
2 months ago
Aug 26, 2024
Sell 382 K USD
Janish Ronald Craig
EVP, Gbl Ops & SC & CTO
- 13000
29.4035 USD
2 months ago
Aug 20, 2024
Sell 571 K USD
Andersen Svend
EVP & President CHCI
- 20500
27.86 USD
2 months ago
Aug 20, 2024
Sell 214 K USD
Andersen Svend
EVP & President CHCI
- 7800
27.455 USD
2 months ago
Aug 20, 2024
Sell 183 K USD
Andersen Svend
EVP & President CHCI
- 6683
27.425 USD
5 months ago
May 28, 2024
Bought 27.9 K USD
Andersen Svend
EVP & President CHCI
+ 1000
27.9 USD
8 months ago
Mar 05, 2024
Bought 67.9 K USD
Ives Alison
EVP & Chief Scientific Officer
+ 2490
27.26 USD
8 months ago
Feb 29, 2024
Bought 40.8 K USD
Ives Alison
EVP & Chief Scientific Officer
+ 1545
26.44 USD
1 year ago
Nov 16, 2023
Bought 59.9 K USD
Ives Alison
EVP & Chief Scientific Officer
+ 2040
29.34 USD
8 months ago
Mar 01, 2024
Bought 9.76 K USD
Willis Robert
EVP & CHRO
+ 371
26.3 USD
8 months ago
Feb 29, 2024
Bought 155 K USD
Willis Robert
EVP & CHRO
+ 6000
25.87 USD
8 months ago
Feb 29, 2024
Bought 252 K USD
Lockwood-Taylor Patrick
CEO
+ 9500
26.544 USD
11 months ago
Nov 24, 2023
Bought 172 K USD
Willis Robert
EVP & CHRO
+ 5550
31.01 USD
1 year ago
Nov 16, 2023
Bought 59.9 K USD
Ives Alison
EVP & Chief Scientific Officer
+ 2040
29.34 USD
1 year ago
Nov 14, 2023
Bought 146 K USD
Bezerra Eduardo Guarita
EVP & Chief Financial Officer
+ 5000
29.1763 USD
1 year ago
Nov 14, 2023
Bought 319 K USD
Lockwood-Taylor Patrick
CEO
+ 11000
28.988 USD
1 year ago
Jun 13, 2023
Bought 331 K USD
Parker Geoffrey M.
Director
+ 10000
33.0637 USD
1 year ago
May 23, 2023
Bought 96.9 K USD
Andersen Svend
EVP & President CHCI
+ 2900
33.4146 USD
1 year ago
May 11, 2023
Sell 7.07 M USD
KESSLER MURRAY S
CEO
- 197646
35.7526 USD
1 year ago
Mar 10, 2023
Sell 321 K USD
Dillard James E III
EVP & President CSCA
- 9000
35.701 USD
1 year ago
Mar 13, 2023
Sell 125 K USD
Farrington Thomas
EVP and CIO
- 3523
35.571 USD
1 year ago
Mar 13, 2023
Sell 7.12 K USD
Farrington Thomas
EVP and CIO
- 200
35.59 USD
1 year ago
Mar 08, 2023
Sell 166 K USD
Janish Ronald Craig
EVP, Gbl Ops & SC & CTO
- 4500
36.9185 USD
1 year ago
Mar 06, 2023
Bought 190 K USD
Parker Geoffrey M.
Director
+ 5000
38.054 USD
1 year ago
Dec 16, 2022
Sell 74.9 K USD
Quinn Grainne
EVP, Chief Medical Officer
- 2368
31.65 USD
2 years ago
Mar 14, 2022
Sell 909 K USD
Farrington Thomas
EVP and CIO
- 24485
37.128 USD
2 years ago
Mar 14, 2022
Sell 84.1 K USD
Farrington Thomas
EVP and CIO
- 2259
37.2301 USD
2 years ago
Mar 04, 2022
Sell 145 K USD
Janish Ronald Craig
EVP, Gbl Ops & SC & CTO
- 3954
36.7305 USD
2 years ago
Dec 17, 2021
Bought 113 K USD
KINGMA TODD W
Executive VP, General Counsel
+ 3000
37.5494 USD
2 years ago
Dec 17, 2021
Bought 113 K USD
KINGMA TODD W
Executive VP, General Counsel
+ 3000
37.5494 USD
2 years ago
Dec 16, 2021
Bought 184 K USD
Parker Geoffrey M.
Director
+ 5000
36.854 USD
2 years ago
Dec 16, 2021
Bought 479 K USD
Alford Bradley A
Director
+ 13000
36.8776 USD
2 years ago
Dec 06, 2021
Bought 46.5 K USD
Andersen Svend
EVP & President CHCI
+ 1255
37.08 USD
2 years ago
Dec 06, 2021
Bought 89.1 K USD
Andersen Svend
EVP & President CHCI
+ 2400
37.11 USD
2 years ago
Dec 03, 2021
Bought 991 K USD
SILCOCK RAYMOND
EVP, Chief Financial Officer
+ 27500
36.0338 USD
2 years ago
Dec 02, 2021
Bought 99.9 K USD
CLASSON ROLF A
Director
+ 2800
35.6693 USD
3 years ago
Mar 17, 2021
Bought 103 K USD
Parker Geoffrey M.
Director
+ 2500
41.2871 USD
3 years ago
Mar 10, 2021
Sell 110 K USD
Janish Ronald Craig
EVP, Gbl Ops & SC & CTO
- 2662
41.2345 USD
7. News
Perrigo (PRGO) International Revenue Performance Explored Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. zacks.com - 5 days ago
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook. zacks.com - 1 week ago
Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript Perrigo Company plc (NYSE:PRGO ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor - President & Chief Executive Officer Eduardo Bezerra - Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Keith Devas - Jefferies Korinne Wolfmeyer - Piper Sandler Daniel Biolsi - Hedgeye Operator Good morning, ladies and gentlemen and welcome to the Perrigo Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode. seekingalpha.com - 1 week ago
Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 week ago
Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates Perrigo (PRGO) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.64 per share a year ago. zacks.com - 1 week ago
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion Infant Formula Business Recovery Making Significant Progress, Including Perrigo Produced and Store Brand Infant Formula Market Share Gains1; Third Quarter 2024 Infant formula Net Sales Growth of +3% Compared to the Prior Year Quarter, +58% Sequentially Reaffirms Fiscal 2024 Adjusted EPS Outlook DUBLIN , Nov. 6, 2024 /PRNewswire/ -- Third Quarter 2024 Highlights: Net sales of $1.1 billion declined 3.2% versus the prior year quarter. Organic2 net sales decreased 2.4%, due primarily to -2.8 percentage points from previously disclosed lost distribution of lower margin products in U.S. Store Brand. prnewswire.com - 1 week ago
Perrigo to Report Q3 Earnings: Here's What to Expect PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter. zacks.com - 1 week ago
Perrigo Announces Quarterly Dividend DUBLIN , Nov. 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on December 17, 2024, to shareholders of record on November 29, 2024. About Perrigo   Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. prnewswire.com - 2 weeks ago
Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024 DUBLIN , Oct. 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2024 financial results on Wednesday, November 6, 2024, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 96443. prnewswire.com - 3 weeks ago
WNBA Star Napheesa Collier Joins Team Opill® for Candid Conversations on Women's Health Opill® and Collier will hit the road to talk to women about their reproductive health options. GRAND RAPIDS, Mich. prnewswire.com - 1 month ago
Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio DUBLIN , Sept. 26, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced a new brand partnership: Good Start®1 and Dr. Brown's® 2 infant formula solutions. prnewswire.com - 1 month ago
PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY DUBLIN , Sept. 17, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the closing of a registered public offering by Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo (the "Issuer"), of $715 million aggregate principal amount of the Issuer's 6.125% Senior Notes due 2032 (the "USD Notes") and €350 million aggregate principal amount of the Issuer's 5.375% Senior Notes due 2032 (the "Euro Notes" and together with the USD Notes, the "Notes"). prnewswire.com - 1 month ago
8. Profile Summary

Perrigo Company plc PRGO

image
COUNTRY IE
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 3.66 B
Dividend Yield 1.07%
Description Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Contact The Sharp Building, Dublin, 2 https://www.perrigo.com
IPO Date Dec. 17, 1991
Employees 9140
Officers Mr. Patrick Lockwood-Taylor President, Chief Executive Officer & Director Mr. Charles Atkinson Executive Vice President, General Counsel & Secretary Mr. Ronald C. Janish Chief Transformation Officer and Executive Vice President of Global Operations & Supply Chain Ms. Alison Ives Executive Vice President & Chief Scientific Officer Mr. Bradley Joseph Vice President of Global Investor Relations & Corporate Communications Ms. Mary Reilly-Brest Director of Global Organizational and Human Resource Development Mr. Svend Andersen Advisor Ms. Kyle L. Hanson Advisor Mr. Shannon Hukill Senior Director of Technical Operations Mr. Eduardo Guarita Bezerra Executive Vice President & Chief Financial Officer